Galectin-3 Is associated with restrictive lung disease and interstitial lung abnormalities

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 1, 2016, Pages 77-83

  Ho, Jennifer E ^a,b   Gao, Wei ^c   Levy, Daniel ^b,d   Santhanakrishnan, Rajalakshmi ^e   Araki, Tetsuro ^f,g   Rosas, Ivan O ^h   Hatabu, Hiroto ^f,g   Latourelle, Jeanne C ^i,j   Nishino, Mizuki ^f,g   Dupuis, Josee ^b,c   Washko, George R ^f,h   O'Connor, George T ^b,i   Hunninghake, Gary M ^f,h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e Cardiovascular Medicine Section   (United Kingdom)

^f Center for Pulmonary Functional Imaging   (United Kingdom)

^g Brigham and Women's Hospital ^*  (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ Pulmonary Center   (United States)

^j BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Biomarker; Epidemiology; Interstitial Lung Disease; Pulmonary Fibrosis

Indexed keywords

CARBON MONOXIDE; GALECTIN 3;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PET-CT SCANNER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ABNORMALITIES; BLOOD; DIAGNOSTIC IMAGING; GENETICS; LUNG; LUNG FUNCTION TEST; ODDS RATIO; X-RAY COMPUTED TOMOGRAPHY;

FEMALE; GALECTIN 3; HUMANS; LUNG; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84988805283     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201509-1753OC     Document Type: Article

References (40)

1. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-171.
2. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060-5065.
3. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-298.
4. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, André S, Crijns HJGM, Gabius HJ, Maessen J, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-3128.
5. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99:323-328.
6. Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA. Elevated plasma galectin-3 is associated with near-Term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. Am Heart J 2014;167:853-860.e4.
7. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-1256.
8. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, et al. Regulation of transforming growth factor-b1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012;185:537-546.
9. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, Kawashima S, Tanabe M, Goto T, Matsuzawa Y, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007;56:57-65.
10. Cullinane AR, Yeager C, Dorward H, Carmona-Rivera C, Wu HP, Moss J, OBrien KJ, Nathan SD, Meyer KC, Rosas IO, et al. Dysregulation of galectin-3: implications for Hermansky-Pudlak syndrome pulmonary fibrosis. Am J Respir Cell Mol Biol 2014;50: 605-613.
11. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Esté par RSJ, Lynch DA, Brehm JM, et al.; COPDGene Investigators. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364: 897-906.
12. Doyle TJ, Washko GR, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Divo MJ, Celli BR, Sciurba FC, Silverman EK, et al.; COPDGene Investigators. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med 2012;185:756-762.
13. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, Nishino M, Araki T, Zazueta OE, Kurugol S, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013;368:2192-2200.
14. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: The Framingham offspring study. Am J Epidemiol 1979;110:281-290.
15. Christenson RH, Duh SH, Wu AHB, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 2010; 43:683-690.
16. Lee HY, Seo JB, Steele MP, Schwarz MI, Brown KK, Loyd JE, Talbert JL, Schwartz DA, Lynch DA. High-resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. Chest 2012;142:1577-1583.
17. Ross JC, Esté par RSJ, Diaz A, Westin CF, Kikinis R, Silverman EK, Washko GR. Lung extraction, lobe segmentation and hierarchical region assessment for quantitative analysis on high resolution computed tomography images. Med Image Comput Comput Assist Interv 2009;12:690-698.
18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
19. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 2002;21: 35-50.
20. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007;31:655-662.
21. Kasper M, Hughes RC. Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol 1996;179:309-316.
22. Sunil VR, Francis M, Vayas KN, Cervelli JA, Choi H, Laskin JD, Laskin DL. Regulation of ozone-induced lung inflammation and injury by the b-galactoside-binding lectin galectin-3. Toxicol Appl Pharmacol 2015;284:236-245.
23. Gebel S, Gerstmayer B, Kuhl P, Borlak J, Meurrens K, Mü ller T. The kinetics of transcriptomic changes induced by cigarette smoke in rat lungs reveals a specific program of defense, inflammation, and circadian clock gene expression. Toxicol Sci 2006;93:422-431.
24. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-1370.
25. Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013;6: 107-117.
26. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One 2011;6:e18683.
27. Garber K. Galecto Biotech. Nat Biotechnol 2013;31:481. [Published erratum appears in Nat Biotechnol 2013;31:773.]
28. FDA approves an IND from Galecto Biotech for TD139 treatment of IPF patients. Phase Ib/IIa trial to start in the UK. Galecto Biotech; 2015 March 1 [accessed 2015 Jul 23]. Available from: http://www.galecto.com
29. Farnworth SL, Henderson NC, Mackinnon AC, Atkinson KM, Wilkinson T, Dhaliwal K, Hayashi K, Simpson AJ, Rossi AG, Haslett C, et al. Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function. Am J Pathol 2008; 172:395-405.
30. Lynch JP III, Standiford TJ, Rolfe MW, Kunkel SL, Strieter RM. Neutrophilic alveolitis in idiopathic pulmonary fibrosis: The role of interleukin-8. Am Rev Respir Dis 1992;145:1433-1439.
31. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 2002; 168:1813-1822.
32. del Pozo V, Rojo M, Rubio ML, Cortegano I, Cá rdaba B, Gallardo S, Ortega M, Civantos E, Ló pez E, Martin-Mosquero C, et al. Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation. Am J Respir Crit Care Med 2002;166:732-737.
33. Ló pez E, Zafra MP, Sastre B, Gámez C, Lahoz C, del Pozo V. Gene expression profiling in lungs of chronic asthmatic mice treated with galectin-3: downregulation of inflammatory and regulatory genes. Mediators Inflamm 2011;2011:823279.
34. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
35. Doyle TJ, Pinto-Plata V, Morse D, Celli BR, Rosas IO. The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 2012;142:1027-1034.
36. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, Bando M, Sugiyama Y, Totani Y, Ishizaki T, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006;11:164-168.
37. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE Jr. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009;135: 1557-1563.
38. Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD, Lubitz SA, Larson MG, Benjamin EJ. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014;167:729-734.e1.
39. OSeaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 2013;24:1470-1477.
40. Putman RK, Rosas IO, Hunninghake GM. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 189:770-778.